News

The latest news for pharma industry insiders.

A sit-down with Groovy Singh, CEO of Bright Green Corporation, who describes the waves in the global supply chain the company is making after being authorized to grow cannabis, along with cannabis-related products.

A qualitative study explores how these drugs are impacting these patients’ lives, while digging deeper into the possibility of deprescribing, with insight from primary care physicians.

The company’s twice-daily, branded ruxolitinib cream 1.5% presents a significant reduction in abscess and inflammatory nodule (AN) count for the treatment of Hurley stage 1 or 2 (mild-to-moderate) hidradenitis suppurativa.

A USC study discovers that an increasing share of both generic and brand-name meds are being excluded from approval.

The latest news for pharma industry insiders.

With out-of-pocket healthcare costs resulting in financial issues for patients, a cross-sectional study closely examines whether they are linked to more premature deaths.

A proposed Senate bill is intended to protect citizens’ private health and genetic information.

The latest news for pharma industry insiders.

The CDMO’s multi-million-dollar expansion project features commercial manufacturing suites and peptide manufacturing plants.

The latest news for pharma industry insiders.

Navigating the complex landscape of healthcare coverage can be an intimidating task, especially for patients with rare diseases for which treatments often come with a high price tag.

The latest news for pharma industry insiders.

The CDC urges healthcare providers to preserve their current supply.

The pTau217 antibody helps pinpoint pathological changes related to the disease.

The latest news for pharma industry insiders.

Momentum from the previous two years will propel the sector into the rest of 2024, says AM Best analysis.

The purchase boosts the parties’ sterile liquid manufacturing capabilities.

The latest news for pharma industry insiders.

A JAMA Network Open study dives into how the utilization of a digital patient portal changed during the COVID-19 pandemic, while also exploring ways that multimorbidity and socioeconomic disparities affected those statistics.

With its aims to protect healthcare consumers against the dangers of counterfeit, contaminated, stolen or otherwise harmful drugs, the DSCSA represents a significant step forward in securing the pharmaceutical supply chain.

The offering reportedly helps avoid product quarantine.

A cohort study investigates a potential correlation between the stresses caused by Mother Nature and mental health.

IPX203—an oral formulation carbidopa/levodopa extended-release capsules —would expand Zambon’s neurology portfolio.

Rob Besse offers a breakdown of the third-party logistics (3PL) process, including lessons that these providers have learned coming out of the pandemic.

In an interview with Pharma Commerce Associate Editor Don Tracy, Corey Ford, VP, Reimbursement & Policy Insights, Cencora, offers his thoughts on where the Inflation Reduction Act will be five to 10 years from now.

A Carrum Health/PWC report surveys benefit managers spanning various self-insured employers in an effort to determine ways to improve the cancer treatment experience, especially from a cost perspective.

An MDVIP study reports that 61% of people feel hassled by the current structure.